The Questions Everyone Is Asking but Few Are Answering Clearly
Over the past few years, GLP-1 receptor agonist medications — including semaglutide and tirzepatide — have shifted the conversation around medical weight loss in a way that has not been seen in decades. The clinical results have been remarkable, the media coverage has been extensive, and the waiting lists at weight loss clinics across Australia have grown significantly.
But alongside the enthusiasm has come confusion. Patients arrive with questions shaped by social media posts, news articles, and friends’ anecdotes — some accurate, some misleading. They want to know whether these medications are safe, how they actually work, whether they will have to take them forever, and whether they are the right choice for their specific situation.
These are entirely reasonable questions. A medication that you inject weekly, that affects your appetite and metabolism, and that requires ongoing medical supervision deserves clear, accurate answers — not marketing language or dismissive reassurance.
How GLP-1 Medications Actually Work
GLP-1 — glucagon-like peptide 1 — is a hormone naturally produced in the gut after eating. It signals the pancreas to release insulin in response to blood glucose, slows gastric emptying, and sends satiety signals to the brain. GLP-1 receptor agonists mimic and extend this signal.
Semaglutide, administered as a weekly subcutaneous injection, binds to GLP-1 receptors and produces sustained activation of the satiety pathway. Patients report that food feels less urgent, portions feel more satisfying, and the constant preoccupation with food — what clinicians call food noise — significantly diminishes. This is not willpower; it is the biological noise being turned down.
Tirzepatide acts on two receptors simultaneously — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) — producing a dual agonist effect that has shown superior weight loss outcomes in clinical trials compared to GLP-1 agonism alone. In large-scale trials, tirzepatide produced average weight reductions of 15 to 20 per cent of body weight in participants with obesity, outcomes that were previously only achievable through bariatric surgery.
Both medications also improve insulin sensitivity, reduce inflammatory markers, and produce measurable cardiovascular benefits in appropriate patient populations.
Common Concerns — and Honest Answers
The most frequently raised concern is side effects. The most common side effects of GLP-1 medications are gastrointestinal — nausea, reduced appetite, constipation, and occasionally vomiting — and they are most pronounced during dose escalation. These effects typically diminish as the body adjusts to the medication. Starting at a low dose and increasing gradually, under medical supervision, minimises their severity.
The question of long-term use is important. GLP-1 medications address the biological drivers of appetite and metabolic dysfunction while they are being taken — they do not permanently reset the underlying biology. For many patients, weight regain follows if the medication is stopped without adequate lifestyle changes in place. This is not a character of the medication; it reflects the chronic nature of obesity as a condition. Ongoing medical review helps determine appropriate duration and dose management.
These medications are not appropriate for everyone. They are contraindicated in personal or family history of medullary thyroid cancer or multiple endocrine neoplasia. They require careful consideration in patients with pancreatitis history, kidney disease, or certain gastrointestinal conditions. Prescribing decisions at NuYu Medical are made by qualified medical practitioners who assess each patient’s full clinical picture before any recommendation is made.
Who Is a Good Candidate for GLP-1 Medication?
GLP-1 medications are generally most appropriate for patients who have a BMI above 30, or above 27 with weight-related health conditions such as type 2 diabetes, hypertension, or metabolic syndrome. They are also considered for patients with insulin resistance who have not responded adequately to lifestyle interventions alone.
They are most effective when prescribed within a programme that includes dietary guidance, physical activity support, and regular clinical monitoring. A patient who begins GLP-1 medication without concurrent changes to eating patterns and lifestyle is less likely to maintain their results than one who uses the medication as part of a comprehensive treatment plan.
The decision to start — and how long to continue — is a clinical one that should be made with a doctor who understands both the medication and the patient’s complete metabolic profile.
Telehealth and Local Care Options
NuYu Medical offers in-person consultations at the Southport clinic, supporting patients across the Gold Coast and Surfers Paradise, as well as telehealth services for individuals throughout Australia. Consultation fees are provided upfront, ensuring transparency and accessibility at every stage of care.
To discuss whether GLP-1 medications are appropriate for your situation, book an appointment online at nuyumedical.com.au/book-appointment/
